Artivila Therapeutics

Artivila Therapeutics is a biotechnology company founded in late 2018, headquartered in Shenzhen, China. The company was co-founded by Dr. Zhendong Zhu and Dr. Deqiang Niu, both of whom have over two decades of experience in the pharmaceutical industry. Dr. Zhu, the chairman, has a background in computational chemistry and previously held roles at Pfizer, Avila Therapeutics, and Celgene. Dr. Niu, the CEO, is a medicinal chemist with prior experience at Biogen, Celgene, and Silicon Therapeutics, having led or participated in advancing over 10 compounds into clinical stages.

Artivila focuses on developing first-in-class and best-in-class small-molecule drugs for therapeutic areas with significant unmet needs, specifically neurodegenerative diseases, autoimmune diseases, and cancers. The company's core is its drug discovery platform, which integrates Artificial Intelligence-Driven Drug Discovery (AIDD) and Computer-Aided Drug Design (CADD) with the team's scientific expertise. This dual-engine approach aims to shorten the R&D cycle, reduce costs, and increase the success rate of identifying novel therapeutic solutions.

The company's business model is centered on leveraging its platform to build a pipeline of proprietary drug candidates. Its pipeline includes therapeutics for oncology (ART-123, ARD-MM1), immunology (ART-04, ART-01, ART-09), and neurodegenerative diseases (ART-08, ART-05). Artivila has successfully identified novel SARM1 inhibitors for conditions like Alzheimer's, Parkinson's disease, and multiple sclerosis. The firm operates on a B2B model, targeting pharmaceutical applications. Since its inception, Artivila has completed three rounds of fundraising, accumulating over 290 million Yuan (approximately $38.8M) from investors including Hike Capital, IMO Ventures, Sinopharm Capital, and Highlight Capital (HLC).

Keywords: AI drug discovery, neurodegenerative diseases, autoimmune diseases, oncology, small-molecule drugs, computational chemistry, CADD, first-in-class therapeutics, drug development, SARM1 inhibitors, biotechnology, medicinal chemistry, pharmaceutical research, Shenzhen, clinical candidates, targeted therapy, molecular design, biopharmaceutical, venture capital, drug pipeline